[KM 155]

Sub. Code: 2052

M.D. DEGREE EXAMINATION.

(Revised Regulations)

Branch IX — Radiotherapy

Part II - Final

Paper III — CANCER CHEMOTHERAPY AND RECENT DEVELOPMENTS IN CLINICAL ONCOLOGY AND RADIOTHERAPY

Time: Three hours

Maximum: 100 marks

Theory: Two hours and

Theory: 80 marks

forty minutes

M.C.Q.: Twenty minutes

M.C.Q.: 20 marks

Answer ALL questions.

Draw suitable diagrams wherever necessary.

I. Essay:

 $(2 \times 15 = 30)$

- (1) Discuss in detail the evolution of organ preservation concept and its present status in the management of Head and Neck cancer.
- (2) Write the detailed staging of Hodgkin's Lymphoma. Describe the various choices of Chemotherapy and the treatment out come in Hodgkin's disease.

II. Short notes :

 $(10 \times 5 = 50)$

- (a) Chemo resistance
- (b) Temozolamide
- (c) Cisplatin and Radiotherapy
- (d) Genetic Testing-indications
- (e) Magnetic Resonance Spectroscopy
- (f) Conformal dose delivery for Ca. Breast
- (g) Use of (18 F) FDG PET in clinical Oncology
- (h) Post Orchiectomy surveillance in seminoma tests
 - (i) IMRT
 - Cytoprotectors.

[KP 153]

Sub. Code: 2052

M.D. DEGREE EXAMINATION.

(Revised Regulations)

Branch IX - Radiotherapy

Paper IV — CANCER CHEMOTHERAPY AND RECENT DEVELOPMENTS IN CLINICAL ONCOLOGY AND RADIOTHERAPY

Time: Three hours

Maximum: 100 marks

Theory: Two hours and

Theory: 80 marks

forty minutes

M.C.Q. : Twenty minutes

M.C.Q.: 20 marks

Answer ALL questions.

Draw suitable diagrams wherever necessary.

- I. Essay questions :
- (1) Classification of Hodgkin's lymphoma Management of Early Hodgkin's disease. (20)
 - Discuss Intensity modulated radiotherapy.
 (15)
- (3) Discuss in detail the role of biological response modifiers. (15)

II. Short notes:

 $(6 \times 5 = 30)$

- (a) Aromatase inhibitors.
- (b) Paranioplastic syndrome.
- (c) Spinal cord compression.
- (d) Hepatocellular carcinoma.
- (e) Docetaxel.
- (f) Neutrons in clinical practise.

[KQ 140] Sub. Code: 2052 M.D. DEGREE EXAMINATION. Branch IX - RADIOTHERAPY CANCER CHEMOTHERAPY AND RECENT DEVELOPMENTS IN CLINICAL ONCOLOGY AND RADIOTHERAPY Common to: Part II - Final Paper III - (Old/New/Revised Regulations) (Candidates admitted from 1988-89 onwards) And Paper IV — (For candidates admitted from 2004-2005 onwards) Time: Three hours Maximum: 100 marks Theory: Two hours and Theory: 80 marks forty minutes

Answer ALL questions.

Draw suitable diagrams wherever necessary.

Discuss - Partial Breast Irradiation.

Discuss - AIDS related malignancies.

Discuss - Conformal radiotherapy.

M.C.Q.: 20 marks

(20)

(15)

(15)

M.C.Q.: Twenty minutes

Essay:

 $(6 \times 5 = 30)$ Short notes: II. CEA. (a) Organ transplantation and cancer. Kaposi's sarcoma. Ibandronic acid. Radioprotectors. EGFR.

[KR 149]

Sub. Code: 2045

II. Short notes :

 $(6 \times 5 = 30)$

M.D. DEGREE EXAMINATION.

Branch - IX - Radiotherapy

Paper IV — CANCER CHEMOTHERAPY AND RECENT DEVELOPMENTS IN CLINICAL ONCOLOGY AND RADIOTHERAPY

(Candidates admitted from 2004 - 2005 onwards)

Time: Three hours

Maximum: 100 marks

Theory: Two hours and

Theory: 80 marks

forty minutes

M.C.Q.: Twenty minutes

M.C.Q. : 20 marks

Answer ALL questions.

Draw suitable diagrams whenever necessary

- I. Essay:
- 1. How do you manage a case of locally advanced Breast Cancer? (20)
- Chemotherapy of Hodgkin's disease. (15)
- 3. Discuss on organ conservation treatment in malignancy. (15)

(b) Vaccine in Ca. Cervix.

Temazolamide.

- (c) Photodynamic therapy.
- (d) Biphosphonates.
- (e) Adriamycin.
- (f) Gene Therapy.

MARCH 2008

[KS 143] Sub. Code: 2038

M.D. DEGREE EXAMINATION.

Branch IX — Radiotherapy

CANCER CHEMOTHERAPY AND RECENT DEVELOPMENTS IN CLINICAL ONCOLOGY AND RADIOTHERAPY

Common to all Regulations

Q.P. Code: 202038

Time: Three hours Maximum: 100 marks

Answer ALL questions.

I. Essays: $(2 \times 20 = 40)$

- (1) Discuss the role of intensity modulated radiation therapy (IMRT) in gynaecological malignancies.
- (2) Discuss the management of stage III ovarian cancer (Adenocarcinoma). Describe the staging and clinical features of carcinoma ovary.
- II. Short notes:

 $(10 \times 6 = 60)$

- (1) Geftinib.
- (2) Chemoprevention.
- (3) SPECT.
- (4) Lasers in oncology.
- (5) Antioxidants.
- (6) GM-CSF.
- (7) Cyclotron.
- (8) Capecitabine.
- (9) Flow cytometry.
- (10) CIN III cervix management and follow-up.